Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
JD HEALTH
06618
5
BIDU-SW
09888
| (Q3)Sep 30, 2025 | (Q2)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 30.08%-5.53M | -25.22%-4.99M | -592.89%-16.28M | -143.01%-31.89M | -455.64%-17.65M | -156.24%-7.91M | -1.52%-3.99M | 22.97%-2.35M | -124.64%-13.12M | -42.12%-3.18M |
| Net income from continuing operations | 58.82%-4.6M | -75.54%-14.4M | -551.15%-24.62M | -156.52%-47.22M | -195.11%-24.08M | -401.89%-11.16M | -100.19%-8.2M | 6.64%-3.78M | -155.37%-18.41M | -197.69%-8.16M |
| Operating gains losses | ---2.63M | --4.85M | 62,457.69%16.21M | --1.08M | --1.11M | ---- | ---- | ---26K | ---- | ---- |
| Depreciation and amortization | 187.14%201K | 342.50%177K | 343.59%173K | 18.04%205.55K | 68.22%56.55K | 35.93%70K | -15.86%40K | -9.32%39K | 23.75%174.13K | -13.93%33.62K |
| Asset impairment expenditure | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | --4.8M | ---- |
| Remuneration paid in stock | -34.34%1.53M | 28.56%1.99M | 98.73%1.88M | 654.63%6.7M | 876.09%1.87M | 909.27%2.32M | 550.44%1.55M | 305.08%946K | 71.93%887.23K | -36.60%192.02K |
| Other non cashItems | --44K | ---18K | -829.81%-319K | ---2.34M | ---2.32M | ---- | ---- | ---34.31K | ---- | ---- |
| Change In working capital | -108.64%-74K | -8.53%2.4M | -2,130.23%-9.6M | 1,766.21%9.68M | 12,661.02%5.73M | 174.78%856K | 2,388.60%2.63M | -34.63%473K | -181.96%-581.18K | -127.81%-45.62K |
| -Change in prepaid assets | -687.10%-732K | 458.76%348K | -753.06%-320K | -586.73%-759.48K | -375.25%-618.48K | -210.89%-93K | -164.27%-97K | -11.80%49K | --156.04K | ---130.14K |
| -Change in payables and accrued expense | -30.66%658K | -24.58%2.05M | -2,289.39%-9.28M | 1,516.56%10.44M | 7,410.59%6.35M | 177.24%949K | 1,124.78%2.72M | -36.53%424K | -193.75%-737.22K | -85.62%84.52K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 30.08%-5.53M | -25.22%-4.99M | -592.89%-16.28M | -143.01%-31.89M | -455.64%-17.65M | -156.24%-7.91M | -1.52%-3.99M | 22.97%-2.35M | -124.64%-13.12M | -42.12%-3.18M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -1,715.87%-92.14M | -33,236.60%-88.34M | -5,673,800.00%-56.74M | -58,321.77%-81.19M | -92,474.67%-75.9M | -9,752.98%-5.07M | -163.97%-265K | 100.76%1K | 101.26%139.45K | 99.25%-81.98K |
| Net PPE purchase and sale | -1,735.32%-93.12M | -38,248.28%-88.97M | -285,140.00%-57.05M | -11,077.00%-32.27M | -29,568.87%-26.94M | -9,752.98%-5.07M | -1,297.49%-232K | 84.75%-20K | -56.59%-288.71K | -20.84%-90.81K |
| Net business purchase and sale | ---- | ---144K | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- |
| Net investment purchase and sale | ---- | ---- | ---- | -11,981.70%-51.14M | -461,244.53%-51.14M | --0 | --0 | --38.75K | --430.42K | --11.09K |
| Interest received (cash flow from investment activities) | --1.04M | --790K | --324K | --2.36M | --2.36M | --0 | --0 | --0 | --0 | ---- |
| Net other investing changes | -27.16%-48K | 0.00%-20K | -161.90%-13K | -6,093.06%-140.05K | ---169.05K | ---37.75K | ---20K | --21K | ---2.26K | ---- |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -1,715.87%-92.14M | -34,956.35%-88.34M | -5,673,800.00%-56.74M | -58,321.77%-81.19M | -92,474.67%-75.9M | -9,752.98%-5.07M | -160.83%-252K | 100.76%1K | 101.26%139.45K | 99.25%-81.98K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 20.45%156.77M | 52,902.11%150.53M | -98.34%433K | 1,773.18%224M | 23,373.34%67.53M | 130.15M | -97.63%284K | 26.07M | -23.66%11.96M | -98.03%287.68K |
| Net issuance payments of debt | -97.30%-73K | ---- | ---- | ---- | ---- | ---37K | ---- | ---- | ---- | ---- |
| Net common stock issuance | --0 | --0 | --0 | 1,059.92%149.95M | -2,708.94%-8.11M | --131.94M | --0 | --26.13M | --12.93M | -40.84%311K |
| Proceeds from stock option exercised by employees | 98.81%837K | 58.10%449K | --507K | --1.19M | --485.09K | --421K | --284K | --0 | --0 | --0 |
| Net other financing activities | 7,265.92%156M | --150.08M | -37.04%-74K | 7,616.03%72.86M | 322,099.13%75.09M | ---2.18M | ---- | ---54K | -106.88%-969.4K | ---23.32K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 20.45%156.77M | 52,902.11%150.53M | -98.34%433K | 1,773.18%224M | 23,373.34%67.53M | --130.15M | -97.63%284K | --26.07M | -23.66%11.96M | -98.03%287.68K |
| Net cash flow | ||||||||||
| Beginning cash position | 311.14%99.93M | 48.83%42.71M | 2,173.17%115.32M | -22.56%4.68M | 1,730.94%142.78M | 120.72%24.31M | 943.62%28.7M | -14.45%5.07M | -16.05%6.05M | 75.19%7.8M |
| Current changes in cash | -49.56%59.1M | 1,546.85%57.19M | -405.93%-72.58M | 10,895.42%110.92M | -775.55%-26.02M | 3,834.17%117.17M | -146.73%-3.95M | 845.86%23.72M | 20.19%-1.03M | -313.52%-2.97M |
| Effect of exchange rate changes | -101.38%-18K | 105.94%26K | 73.00%-27K | -727.66%-293.34K | -1,233.40%-1.06M | 1,809.58%1.31M | -609.16%-438K | -82.39%-100K | 1,090.79%46.74K | 688.06%93.82K |
| End cash Position | 11.37%159.01M | 311.14%99.93M | 48.83%42.71M | 2,176.25%115.31M | 2,176.25%115.31M | 1,730.94%142.78M | 115.18%24.31M | 965.11%28.7M | -14.28%5.07M | -14.28%5.07M |
| Free cash from | -659.92%-98.65M | -2,128.08%-93.96M | -2,995.15%-73.32M | -378.35%-64.16M | -1,264.75%-44.59M | -313.75%-12.98M | -6.98%-4.22M | 25.52%-2.37M | -122.56%-13.41M | -41.43%-3.27M |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.